Comparative Pharmacology
Head-to-head clinical analysis: COMPRO versus PROMETHAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COMPRO versus PROMETHAZINE HYDROCHLORIDE.
COMPRO vs PROMETHAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prochlorperazine is a phenothiazine antipsychotic that primarily acts as a dopamine D2 receptor antagonist, with additional antagonism at D3, 5-HT2A, alpha1-adrenergic, and histamine H1 receptors. It also has antiemetic effects via D2 blockade in the chemoreceptor trigger zone.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and antidopaminergic properties.
5 to 10 mg intramuscularly every 3 to 4 hours as needed; or 5 to 10 mg intravenously at a rate not exceeding 5 mg per minute; or 10 mg orally every 6 to 8 hours; maximum daily dose 40 mg.
25-50 mg intramuscular or intravenous injection every 4-6 hours as needed; also 12.5-25 mg orally every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults (prolonged in hepatic impairment, cirrhosis up to 10-12 hours; neonates up to 24 hours).
Terminal elimination half-life is 10-19 hours in adults; prolonged in hepatic impairment (up to 30+ hours) and in elderly.
Renal: 70-80% as glucuronide and sulfate conjugates; biliary/fecal: <10% unchanged; <5% as unchanged drug in urine.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <1% of unchanged drug; biliary/fecal excretion of metabolites ~70-80%.
Category C
Category A/B
Antiemetic
Antihistamine / Antiemetic